New scan could reveal how well immunotherapy works in real time

NCT ID NCT06534190

First seen Feb 14, 2026 · Last updated May 11, 2026 · Updated 11 times

Summary

This study tests a special imaging agent (89Zr-DF-Crefmirlimab) that helps PET scans show where immune cells called CD8 T-cells are in the body. About 30 adults with advanced solid tumors will receive this agent before and during standard immunotherapy. The goal is to see if the scan can predict or track how well the immune system attacks the cancer, which could help doctors personalize treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University Medical Center Groningen

    RECRUITING

    Groningen, 9713 GZ, Netherlands

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Cambridge

    NOT_YET_RECRUITING

    Cambridge, CB2 1TN, United Kingdom

    Contact

    Contact

  • VUMC

    RECRUITING

    Amsterdam, 1081 HV, Netherlands

    Contact

    Contact

  • Vall d'Hebron Institute of Oncology (VHIO) / Vall d'Hebron Institute Research (VHIR)

    NOT_YET_RECRUITING

    Barcelona, 08035, Spain

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.